Navigation Links
Concentric Medical Announces Product and Procedure Reimbursement as Well as Full Commercialization of the Merci Retriever® in Japan
Date:10/4/2010

MOUNTAIN VIEW, Calif., Oct. 4 /PRNewswire/ -- Concentric Medical, Inc., the global leader in devices for clot removal in ischemic stroke patients, today announced that the Merci Retriever® has recently received both product and procedure reimbursement from the Japanese Ministry of Health, Labor and Welfare.  The Merci Retriever is a catheter-based medical device that physicians at stroke centers use to remove blood clots from the brains of patients suffering an ischemic stroke.

On May 4th, Concentric Medical announced the Shonin approval of the Merci Retriever®, Merci® Microcatheter, and Merci® Balloon Guide Catheter.  

Nobuyuki Sakai, M.D., D.M.Sc., Director, Neurosurgery & Stroke Center at Kobe City General Hospital said, "The Merci Retriever is quickly becoming a very meaningful treatment option for acute stroke patients in Japan.  The initial cases at leading stroke institutions since Shonin approval have been very successful.  Reimbursement for the Merci Retriever and the mechanical procedure are a critical part of making the Merci system available to all neurosurgeons, neurologists, and hospitals in Japan that treat acute stroke patients."

Century Medical, Inc. is the exclusive distribution partner for Concentric Medical in Japan.  The two companies worked together to obtain both Shonin approval and reimbursement for the Merci Retriever, which is the first device for clot removal for ischemic patients to be approved in Japan.

One of Concentric Medical's strategic objectives has been global expansion. The incidence of stroke and the mortality and disability associated with stroke are very significant issues for health care systems across the world.  Maria Sainz, President and CEO of Concentric Medical said, "We are honored to be the first to offer a device solution for stroke patients in Japan. Launching the Merci system in Japan is a very significant milestone and a great new opportunity for growth for our company.  With over 1,300 patients enrolled in clinical studies, we believe Merci has been proven to be a very effective tool in revascularizing stroke patients."

Akira Hoshino, President and CEO of Century Medical, Inc. said, "Century Medical is extremely excited to bring such a valuable and innovative therapy to Japan.  The reimbursement for both the Merci Retriever and procedure related to mechanical thrombectomy with the Merci Retriever are an essential part of the introduction of this new treatment.  Century Medical is committed to pioneering stroke treatment in Japan by working closely with physicians and hospitals to make the Merci Retriever widely available for Japanese stroke patients."

About Concentric MedicalConcentric Medical is located in Mountain View, California and is the global leader in the development of endovascular devices for revascularizing stroke patients.  The company manufactures and markets solutions for ischemic stroke: minimally invasive devices that are delivered into the brain to restore blood flow by removing blood clots that cause ischemic stroke.  Concentric Medical's devices are available in over 500 leading stroke centers around the world, and have been the subject of several clinical studies.  For more information about Concentric Medical, please visit www.concentric-medical.com.

About Acute Ischemic StrokeStroke is the third leading cause of death in the developed world and the leading cause of serious long-term disability. Ischemic stroke represents over 85% of strokes and occurs when a blockage or clot develops in one of the arteries supplying blood to the brain. In 2004 the FDA cleared Concentric Medical's Merci Retriever for use in stroke patients who are ineligible for IV-tPA or who fail to respond to IV-tPA therapy. This pioneering device created a departure from the historic method of caring for stroke patients and offered physicians and patients a long-awaited option for stroke intervention.

For more information about Concentric Medical, please visit www.concentric-medical.com.Media Contact: +1 650-938-2100strokeinfo@concentric-medical.com
'/>"/>

SOURCE Concentric Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Concentric Medical to Sponsor Randomized Trial
2. Concentric Medical and the Merci Retrieval System(R) Highlighted at the 2010 International Stroke Conference
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. Globus Medical Raises $110 Million in Series E Financing Round
7. Quark Pharmaceuticals Appoints New Chief Medical Officer
8. Boston University Biomedical Engineers Find Chink in Bacterias Armor
9. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
10. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... KEY FINDINGS North America ... market in 2016 and is expected to continue in ... a large number of surgical procedures that are taking ... in the patient temperature management market.) Patient warming and ... of blood during surgeries, lowering the risks of neurological ...
(Date:12/8/2016)... , Dec 8, 2016 Research and ... Market Analysis and Trends - Adhesion Type, Application, Usability - Forecast ... ... Global Cardiology Electrodes Market is poised to grow at a CAGR ... trends that the market is witnessing include advancements in extracellular microelectrode ...
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
Breaking Medicine Technology:
(Date:12/9/2016)... PA (PRWEB) , ... December 09, 2016 , ... An ... permit amputees to safely ride all types of amusement park rides. , The patent-pending ... the unit is easy to use and could be set up in a matter ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... Pennsylvania Cable Network (PCN) during the summer of 2016. The program was made ... by the United States Department of Health and Human Services Administration. The ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for Input ... JMIR Medical Informatics . , Results of the comparative usability study demonstrate that ...
(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick ... West, Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is ... Sciences & Medical Technology Group have been featured speakers at every DeviceTalks conference since ...
(Date:12/8/2016)... ... 2016 , ... STATEN ISLAND, N.Y., Nov. 24, 2016 — ... highest standards of trauma, maternity, cancer and chronic obstructive pulmonary disease (COPD) services ... Daniel Messina. , Among the recognitions, the American College of Surgeons' (ACS) named ...
Breaking Medicine News(10 mins):